Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer

Inclusion Criteria: * Informed consent form signed before performing any of the study's specific procedures. * ECOG performance status 0-2. * Age \> 18，both genders. * Metastatic colorectal cancer confirmed by pathology, or locally advanced unresectable colorectal cancer, or postoperative recurrence and metastasis colorectal cancer * Disease progression after receiving oxaliplatin ± fluorouracil in first-line treatment * At least 1 measurable lesions ,( longest diameter≥ 1 cm by spiral computed tomography (CT) scan or MRI) * Life expectancy more than 3 months. * K-ras is wild type * Use of an effective contraceptive method for patients of both sexes when there is a risk of conception and/or pregnancy. * Liver metastasis, lesions smaller than 50% of the liver; Lung metastasis, lesions smaller than 30% of the lung * Haemoglobin≥90g/L , granulocyte≥1.5×109/L ,WBC ≥3×109/L, platelet count≥100×109/L * TBIL≤ 1.5 x ULN ,ALK≤ 2.5 x ULN or ≤ 5ULN（Liver metastasis），AST and ALT≤ 2.5 x ULN or ≤ 5ULN（Liver metastasis）,Creatinine ≤ 1.5 x ULN * No brain metastasis Exclusion Criteria: * Previous radiotherapy at lesions within three months * Other first line chemo-agents treatment except oxaliplatin ± fluorouracil * Received other anti EGFR monoclonal antibody treatment * Complete or incomplete intestinal obstruction * Participation in other interventional clinical trials within 1 month * Psychiatric disease affected cognitive ability, including brain metastasis * Peripheral neuropathy lesion is more than I stage. * History of serious allergic or allergy * Pregnant or breast-feeding women * Patients with the history of Serious lung or hear disease * Other malignant tumor